SEP 2 2 2003 ME

Subality toppedin 1449A/PTO

PTO/SB/08a (05-03) (AW 07/03)
Approved for use through 05/31/03. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Onder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 1

	Complete if Kn wn	
Application Number	09/943,687	
Filing Date	August 31, 2001	
First Named Inventor	Kamel F. Egbaria et al.	
Art Unit	1653	
Examiner Name		
Attorney Docket No.	MGP-104US	

			U.S. PATENT	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number - Kind Code ^{2 (if known)}	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Clerk Appear
my	1	US-5,965,160	10-12-1999	Benita et al.	424 145
14-1-		US-			11/1/13
	*	US-			
		US-			
***************************************		US-			
		US-	<u> </u>		
		US-			
		US-			
		US-	<u> </u>		
		US-			
		US-	[1

	FOREIGN PATENT DOCUMENTS										
-	6 714 -	Foreign Patent Document	Dublication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	:					
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)	Publication Date (MM-DD-YYYY)	Applicant of Cited Document	Passages or Relevant Figures Appear	76					

			<i></i>	1
Examiner Signature	Abdel A. Molicines Date Considered	7 [70/	03
3.3		/	~	

¹Applicant's unique citation designation number (optional).

²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

					·		et <u>1</u> of
FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT PATENT AND TRAD		ATTY, DOCKET NO. MGP-104US	SERIAL 09/943	_ NO ,687		CEN
	ormation Disclosement by Applic		APPLICANT Kamel F. Egbaria et al.			- RE	EP 06
(liea	several sheets if necess		FILING DATE	GROUP		3	L CENTE
**************************************			August 31, 2001	1653			1000
	l Dames		TENT DOCUMENT	S	Cl	T	T
Exmr Initial	Document Number	Date	Name		Class	Sub Class	Filing Date
					- 00	PPY OF PA	PERS -
		FOREIGN	PATENT DOCUME	NTS			
Exmr Initial	Document Number	Date	Country		Class	Sub Class	Translation YES NO
	(Tuc		ER DOCUMENTS Title, Date, Pertinent Page	ges, Etc.)			
	JIII)		issuence of oleic acid on the forma		taneous em	ulsion," S.T.F	P. Pharma
AM	Li, Y. and	Groves, M., "The II 0 (4) 341-344 2000					
AM .	Li, Y. and	Groves, M., "The II 0 (4) 341-344 2000					
an _	Li, Y. and	Groves, M., "The II 0 (4) 341-344 2000					
AM _	Li, Y. and	Groves, M., "The II 0 (4) 341-344 2000					
AM	Li, Y. and	Groves, M., "The II 0 (4) 341-344 2000					

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USPTO Form 1449 [R&P]

	4		FORM PTO-1449					
						She	et <u>1</u> c	
FORM PTO-1449	J.S. DEPARTMENT	OF COMMERCE	ATTY, DOCKET NO.	SERIA	SERIAL NO			
	PATENT AND TRADE		MGP-104US	09/94	3,687			
	nation Disclosi	ire	APPLICANT					
	ent by Applic		Kamel F. Egbaria et al.					
SIPE (Use sev	eral sheets if necessa	ry)	FILING DATE	GROU				
0		••	August 31, 2001	1653	•			
APR 0 5 2002		U.S. P	ATENT DOCUMENT					
Exmr ks	Document	Date	Name		Class	Sub	Fili	
Exmr	Number		• • • • • • • • • • • • • • • • • • • •			Class	Dat	
							 	
	<u> </u>				<u> </u>		 -	
					-0	VED		
						VLL		
					APR 0	2002	 	
		-		TEC	CENTE	1600/26	100-	
		FOREIG	N PATENT DOCUME	NTS				
Exmr Initial	Document	Date	Country		Class	Sub	Transla YES	
minai	Number					Class		
	(·	-	
	 						 -	
							<u></u>	
			HER DOCUMENTS				<u> </u>	
		uding Auth	or, Title, Date, Pertinent Pa					
	1) Craig et a	uding Auth	or, Title, Date, Pertinent Pastigation into the effects of dr	ug inclusio	on on the d			
And	Craig et a	uding Auth al., "An investorsion and di	or, Title, Date, Pertinent Pa	ug inclusio	on on the d			
Ary	Craig et a surface to Journal of Shah et a	uding Auth al., "An invest ension and di f Pharmaceuts l., "Self-emu	or, Title, Date, Pertinent Pastigation into the effects of droplet size distribution of selfics, 96:147-155, 1993. Isifying drug delivery system	ug inclusionerus	on on the d ng systems) with poly	glycolyzed	ional	
Ary	Craig et a surface to Journal of Shah et a glyceride	uding Authal., "An investion and different Pharmaceuthal., "Self-emuss for improving the second seco	or, Title, Date, Pertinent Pastigation into the effects of droplet size distribution of selfics, 96:147-155, 1993. Ilsifying drug delivery systeming in vitro dissolution and or	ug inclusion emulsifying (SEDDS)	on on the d ng systems) with poly	glycolyzed	ional	
My	1) Craig et a surface to Journal of Shah et a glyceride Internatio	uding Authal., "An investing and different for improving the land of the land	or, Title, Date, Pertinent Pastigation into the effects of drapplet size distribution of self- ics, 96:147-155, 1993. Alsifying drug delivery systeming in vitro dissolution and orange of Pharmaceutics, 106:15-23, 19	ug inclusion emulsifyi (SEDDS) al absorption	on on the d ng systems) with poly on of lipop	glycolyzed	ional	
My	1) Craig et a surface to Journal of Shah et a glyceride Internation Biopharm	uding Authal., "An investigation and difference of the Pharmaceutics for improving all Journal of the Edit of the	or, Title, Date, Pertinent Pastigation into the effects of draplet size distribution of self-ics, 96:147-155, 1993. Alsifying drug delivery systeming in vitro dissolution and orange of Pharmaceutics, 106:15-23, 196:Emulsifying Drug Delivery luation of an Investigational I	ug inclusionemulsifying (SEDDS) al absorptionemulsifying (SEDDS) al absorptionemulsi (Sentencemulsi (Sentencemu	on on the d ng systems) with poly on of lipop	glycolyzed hilic drugs	ional	
My	1) Craig et a surface to Journal of Shah et a glyceride Internation Biopharm	uding Authal., "An investigation and defined for the second for th	or, Title, Date, Pertinent Pastigation into the effects of draplet size distribution of self-ics, 96:147-155, 1993. Alsifying drug delivery systeming in vitro dissolution and orange of Pharmaceutics, 106:15-23, 196:Emulsifying Drug Delivery luation of an Investigational I	ug inclusionemulsifying (SEDDS) al absorptionemulsifying (SEDDS) al absorptionemulsi (Sentencemulsi (Sentencemu	on on the d ng systems) with poly on of lipop	glycolyzed hilic drugs	ional	
My	1) Craig et a surface to Journal of Shah et a glyceride Internation Biopharm	uding Authal., "An investigation and difference of the Pharmaceutics for improving all Journal of the Edit of the	or, Title, Date, Pertinent Pastigation into the effects of draplet size distribution of self-ics, 96:147-155, 1993. Alsifying drug delivery systeming in vitro dissolution and orange of Pharmaceutics, 106:15-23, 196:Emulsifying Drug Delivery luation of an Investigational I	ug inclusionemulsifying (SEDDS) al absorptionemulsifying (SEDDS) al absorptionemulsi (Sentencemulsi (Sentencemu	on on the d ng systems) with poly on of lipop	glycolyzed hilic drugs	ional	

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	4,719,239	01/12/88	Muller et al.	5/4	785	
	4,783,332	11/08/88	Schreuder	424	54	
	4,943,560	07/24/90	Wigness et al.	514	1/	
	5,294,604	03/15/94	Nussenblatt et al.	5/4	11	
	5,504,068	04/02/96	Komiya	64	11	
	5,583,105	12/10/96	Kovács et al.	ric	71	
	5,639,474	06/17/97	Woo	424	452	
	5,670,478	09/23/97	Stuchlik et al.	5/4	11	
	5,759,997	06/02/98	Cavanak	2514	17	
	5,958,876	09/28/99	Woo	614	11	
	5,962,014	10/05/99	Hauer et al.	7/24	450	
	5,962,019	10/05/99	Cho et al.	424	45	
	5,998,365	12/07/99	Sherman	574	11	
	6,008,192	12/28/99	Al-Razzak et al.	614	//	
	6,063,762	05/16/00	Hong et al.	514	11	
	· ·				- ,	

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date		Country	Class	Sub Class	Trans YES	lation NO
	WO99/44,584	09/10/99	PCT					
	 	<u> </u>						

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

311: 242-255, 1986

Examiner	Abdel	A. Moham	Date Considered	9/30/03	

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

V